CytoPak GMP Human IL-7 Protein (E. coli)

  • No equivalent PG product available.
用户评价
货号-规格
价格
Qty.
CytoPak
GMP-L07H15GB02-50ug
询价
GMP lyophilized
GMP-L07H15-50ug
¥6605.00
GMP-L07H15-500ug (50ug X 10)
¥22995.00
GMP-L07H15-1mg (50ug X 20)
¥35455.00
CytoPak
GMP-L07H15GB01-10ug
询价
合计0件 产品金额¥ 0

产品详情

  • IL-7 Product Show

    CytoPak GMP Human IL-7 Protein (E. coli) is packaged in sterile closed containers that can be readily incorporated into ex vivo clinical production processes. The bag utilizes medical grade multilayer film with two weldable options. The outlet weldable tube contains a proximal TPE section (1/8’’ ID x 1/4’’ OD) and a distal PVC section (3/32’’ ID x 5/32’’ OD). The liquid state and closed-system packaging of CytoPak GMP Human IL-7 Protein (E. coli) can be directly welded to GMP media bags resulting in safety and user-friendliness by bypassing the reconstitution step during manufacture.

  • 优势特色(Features)

    1. Closed System Process
    2. Minimized Manual Touchpoints
    3. Ready-to-Use Format
    4. Enhanced Efficiency
    5. Weldable Tubing
    6. Designed under ISO 9001:2015 and ISO 13485:2016
    7. Manufactured and QC tested under a GMP compliance factory
    8. Animal-Free Materials
    9. Beta-lactam Materials Free
    10. Batch-to-batch Consistency
  • 表达区间及表达系统(Source)

    CytoPak GMP Human IL-7 Protein (E. coli) (GMP-L07H15GB02) is expressed from E. coli cells. It contains AA Asp 26 - His 177 (Accession # P13232-1).

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    IL-7 Structure

    This protein carries no "tag".

    The protein has a calculated MW of 17.5 kDa. The protein migrates as 17 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

  • N端测序(N-terminal Sequence Analysis)

    Met-Asp-Cys-Asp-Ile-Glu-Gly-Lys-Asp-Gly-Lys-Gln-Tyr-Glu-Ser
    (Routinely tested)

  • 内毒素(Endotoxin)

    Less than 1.0 EU/mL, tested by the rFC method in compliance with USP <86> and Ph. Eur. 2.6.32.

  • 宿主蛋白残留(Host Cell Protein)

    <0.5 ng/µg of protein tested by ELISA.

  • 宿主核酸残留(Host Cell DNA)

    <0.02 ng/μg of protein tested by qPCR.

  • 无菌(Sterility)

    Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

  • 支原体(Mycoplasma)

    Negative

  • 纯度(Purity)

    >95% as determined by SDS-PAGE.

  • 制剂(Formulation)

    Supplied as 0.2 μm filtered solution in PBS, rHSA, pH7.4 with protectants.

    Contact us for customized product form or formulation.

  • 运输(Shipping)

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • 存储(Storage)

    Upon receipt, store it immediately at -20°C or lower for long term storage.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. Can be stored up to 24 months at -20°C;
    2. Can be stored up to 2 weeks at 2-8°C.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • 电泳(SDS-PAGE)

    IL-7 SDS-PAGE

    CytoPak GMP Human IL-7 Protein (E. coli) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • 活性(Bioactivity)-CELL BASE

     IL-7 CELL

    CytoPak GMP Human IL-7 Protein (E. coli) (Cat. No. GMP-L07H15GB02) stimulates proliferation of PHA-P-activated human peripheral blood mononuclear cell (PBMC). The specific activity of CytoPak GMP Human IL-7 Protein (E. coli) is > 1.00ⅹ10^8 IU/mg, which is calibrated against human IL-7 WHO International Standard (NIBSC code: 90/530) (QC tested).

    Protocol
  • 应用数据(Application Data)

     IL-7 APPLICATION DATA

    Human PBMCs were cultured with lyophilized GMP Human IL-7 Protein (ACROBiosystems, Cat. No. GMP-L07H15) or CytoPak GMP Human IL-7 Protein (ACROBiosystems, Cat. No. GMP-L07H15GB02) or CytoPak GMP Human IL-7 Protein (ACROBiosystems, Cat. No. GMP-L07H15GB01) and GMP Human IL-15 Protein (ACROBiosystems, Cat. No. GMP-L15H13) for 13 days. The result shows that there was no significant difference between lyophilized IL-7 and CytoPak IL-7.

  •  IL-7 APPLICATION DATA

    Human PBMCs were cultured with lyophilized GMP Human IL-7 Protein (ACROBiosystems, Cat. No. GMP-L07H15) or CytoPak GMP Human IL-7 Protein (ACROBiosystems, Cat. No. GMP-L07H15GB02) or CytoPak GMP Human IL-7 Protein (ACROBiosystems, Cat. No. GMP-L07H15GB01) and GMP Human IL-15 Protein (ACROBiosystems, Cat. No. GMP-L15H13) for 13 days. No significant differences were observed in the ratio of CD3+ or CD3+ CD4/CD8 positive cells between lyophilized and CytoPak IL-7.

  • 稳定性(Stability)

     IL-7 STABILITY

    The Cell based assay shows that CytoPak GMP Human IL-7 Protein (E. coli) (Cat. No. GMP-L07H15GB02) is stable at 37°C for 15 days.

  •  IL-7 STABILITY

    The Cell based assay shows that CytoPak GMP Human IL-7 Protein (E. coli) (Cat. No. GMP-L07H15GB02) is stable after freezing and thawing 3 times.

用户评价
发表评论

背景介绍

Interleukin 7 is also known as IL7, IL-7, and is a hematopoietic growth factor secreted by stromal cells in the red marrow and thymus. It is also produced by keratinocytes, dendritic cells, hepatocytes, neurons, and epithelial cells, but is not produced by lymphocytes. IL-7 stimulates the differentiation of multipotent (pluripotent) hematopoietic stem cells into lymphoid progenitor cells, It also stimulates proliferation of all cells in the lymphoid lineage (B cells, T cells and NK cells). It is important for proliferation during certain stages of B-cell maturation, T and NK cell survival, development and homeostasis. IL-7 is a cytokine important for B and T cell development. This cytokine and the hepatocyte growth factor (HGF) form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. IL-7 binds to the IL-7 receptor, a heterodimer consisting of Interleukin-7 receptor alpha and common gamma chain receptor. Il-7 promotes hematological malignacies (acute lymphoblastic leukemia, T cell lymphoma). Elevated levels of IL-7 have also been detected in the plasma of HIV-infected patients. IL-7 as an immunotherapy agent has been examined in many pre-clinical animal studies and more recently in human clinical trials for various malignancies and during HIV infection. IL-7 could also be beneficial in improving immune recovery after allogenic stem cell transplant.

重要声明

  • MANUFACTURING SPECIFICATIONS

    ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP<92>Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP<1043>Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.

    ACROBiosystems Quality Management System Contents:

    1. Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory
    2. Animal-Free materials
    3. Materials purchased from the approved suppliers by QA
    4. ISO 5 clean rooms and automatic filling equipment
    5. Qualified personnel
    6. Quality-related documents review and approve by QA
    7. Fully batch production and control records
    8. Equipment maintenance and calibration
    9. Validation of analytical procedures
    10. Stability studies conducted
    11. Comprehensive regulatory support files

    Request For Regulatory Support Files(RSF)

    ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

    1. SDS-PAGE
    2. Protein content
    3. Endotoxin level
    4. Residual Host Cell DNA content
    5. Residual Host Cell Protein content
    6. Biological activity analysis
    7. Microbial testing
    8. Mycoplasma testing
    9. In vitro virus assay
    10. Batch-to-batch consistency

  • ACROBIOSYSTEMS - LEGAL NOTICES FOR GMP GRADE PRODUCTS

    1. PRODUCT USE RESTRICTIONS & PROHIBITIONS

    • 1.1 ACROBiosystems ("ACRO") GMP grade products ("Products") are designed for research, manufacturing use or ex vivo use.
    • 1.2 Products are NOT intended for diagnostic purposes or for direct or indirect administration into humans.
    • 1.3 Purchaser shall not market, distribute, or resell Products obtained from ACRO without ACRO's prior written consent.

    2. REVERSE ENGINEERING PROHIBITED & CONFIDENTIALITY

    • 2.1 Purchaser shall not reverse-engineer, decompile, disassemble, sequence, analyze via bioinformatics, or otherwise attempt to discover the structure, sequence, composition, construction, manufacturing process, or any trade secret embodied in the Products. Purchaser shall not permit any third party to undertake such activities.
    • 2.2 All specifications, data, and know-how related to the Products provided by ACRO are ACRO's confidential information and shall be protected accordingly.

    3. LIMITED WARRANTY & DISCLAIMERS

    • 3.1 ACRO warrants solely that Products will conform to their published specifications when used under normal, specified laboratory/manufacturing conditions and within their labeled expiration date. THIS IS THE ONLY WARRANTY PROVIDED.
    • 3.2 Purchaser assumes ALL risk and responsibility for:
      (a) Determining the suitability of Products for Purchaser's intended application(s).
      (b) Obtaining any necessary regulatory approvals or intellectual property licenses for Purchaser's use.
      (c) Compliance with all applicable laws, regulations (including but not limited to cGMP/GLP where claimed), and industry standards.
      (d) Conducting all necessary quality control, safety, efficacy, and validation testing of Products within Purchaser's process or final product.
      (e) Proper storage, handling, and use of Products according to ACRO's instructions.
    • 3.3 ACRO EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, INCLUDING BUT NOT LIMITED TO: (A) WARRANTIES OF MERCHANTABILITY; (B) WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE; (C) WARRANTIES OF NON-INFRINGEMENT; AND (D) WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE.

    4. LIMITATION OF LIABILITY

    • IN NO EVENT SHALL ACRO, ITS AFFILIATES, OR SUPPLIERS BE LIABLE FOR ANY OF THE FOLLOWING, HOWSOEVER ARISING (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, STATUTE, OR OTHERWISE):
      (a) LOST PROFITS, LOST REVENUE, LOST SAVINGS, LOSS OF USE, LOSS OF DATA, BUSINESS INTERRUPTION, OR ANY OTHER INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES.
      (b) ANY DIRECT DAMAGES, COSTS, OR EXPENSES EXCEEDING THE AMOUNT PAID BY PURCHASER FOR THE SPECIFIC PRODUCT(S) GIVING RISE TO THE CLAIM.
      (c) DAMAGES ARISING FROM: (i) MISUSE, ABUSE, OR UNAUTHORIZED MODIFICATION OF PRODUCTS; (ii) USE BEYOND THE EXPIRATION DATE; (iii) IMPROPER STORAGE OR HANDLING; (iv) ACCIDENTAL DAMAGE; (v) FAILURE TO CONDUCT ADEQUATE VALIDATION OR TESTING BY PURCHASER; (vi) INFRINGEMENT CLAIMS RELATED TO PURCHASER'S USE; OR (vii) THE COST OF PROCURING SUBSTITUTE GOODS OR SERVICES.
      (d) ANY PERSONAL INJURY, DEATH, OR DAMAGE TO TANGIBLE PROPERTY TO THE EXTENT PERMITTED BY LAW.

    5. END USER ACKNOWLEDGEMENT & COMPLIANCE

    • 5.1 By accepting, opening, or using the Products, the End User (Purchaser or its downstream recipient) agrees to be irrevocably bound by all terms herein.
    • 5.2 End User explicitly acknowledges the Products are NOT FOR HUMAN ADMINISTRATION and agrees not to use them in any in vivo human application, directly or indirectly.
    • 5.3 End Users unwilling to accept these terms must immediately: (a) cease all use; (b) notify ACRO or their supplier; and (c) return the unopened, unused Products. 5.4 ACRO reserves the right to audit End User's compliance with these restrictions upon reasonable notice

    ACRO has the right, at its sole discretion, to modify, add or remove any terms herein without notice to Purchaser and/or End User. Any changes to these terms are effective immediately following the updating of such changes on ACRO’s website or published specifications or product-related documents

前沿进展

 
药物研发进展
  • 英文全称:

    Interleukin-7

  • 中文全称:

    白介素7

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    4 详情

  • 最高研发阶段:

    临床一期

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍
  • 重要声明